Canada approves second generic Ozempic, slashing diabetes drug costs

Canada approves second generic Ozempic, slashing diabetes drug costs

Blue background with white text and logo stating "19 million Americans will save an estimated $400 per year on prescription drug costs".

Canada approves second generic Ozempic, slashing diabetes drug costs

Health Canada has approved a second generic version of Ozempic, making it the first G-7 nation to greenlight generic semaglutide. The medication, produced by Toronto-based Apotex, is cleared for treating Type 2 diabetes in adults. This move follows the earlier approval of the first generic alternative to Novo Nordisk’s brand-name drug. The newly approved generic contains the same active ingredient, semaglutide, as Ozempic. While Ozempic is also widely prescribed off-label for weight loss, its official use remains for diabetes management.

Pricing for generics typically follows a predictable pattern. The first generic version usually costs between 75 and 85 per cent of the brand-name price. Once a second generic enters the market, both versions drop to around 50 per cent of Ozempic’s original cost. With three or more generics available, the price could fall further—to roughly 35 per cent of the brand-name drug’s price. Apotex, a global pharmaceutical firm, now joins the market alongside the first approved generic manufacturer.

The approval of Apotex’s semaglutide introduces more competition into Canada’s diabetes medication market. Lower prices are expected as additional generics become available. This decision positions Canada as the first among major economies to offer generic alternatives to Ozempic.

Neueste Nachrichten